Clinical Advances in Hematology & Oncology最新文献_第2页

Fruquintinib as post-standard third-line therapy in a patient with mCRC without targetable mutations: a real-world application of FRESCO trial principles. fruquininib作为无靶向突变的mCRC患者的标准后三线治疗：FRESCO试验原则的实际应用

IF 2

Clinical Advances in Hematology & Oncology Pub Date : 2026-07-01

Maen Hussein

引用次数: 0

Involvement of the central nervous system in CLL. 中枢神经系统在CLL中的受累。

IF 2

Clinical Advances in Hematology & Oncology Pub Date : 2026-07-01

Thomas Chatzikonstantinou

引用次数: 0

Highlights in gynecologic cancer from the 2026 American Society of Clinical Oncology Annual Meeting. 来自2026年美国临床肿瘤学会年会的妇科癌症亮点。

IF 2

Clinical Advances in Hematology & Oncology Pub Date : 2026-07-01

Ursula A Matulonis

引用次数: 0

The microbiome in kidney cancer. 肾癌中的微生物组。

IF 2

Clinical Advances in Hematology & Oncology Pub Date : 2026-07-01

Shahla Bari

引用次数: 0

Could bispecific antibodies be used as consolidation treatment after R-CHOP for DLBCL? 双特异性抗体能否作为DLBCL R-CHOP后的巩固治疗？

IF 2

Clinical Advances in Hematology & Oncology Pub Date : 2026-07-01

Matthew A Lunning

引用次数: 0

Artificial intelligence in prostate cancer diagnosis and management: state-of-the-art approaches and emerging innovations. 人工智能在前列腺癌诊断和管理：最先进的方法和新兴的创新。

IF 2

Clinical Advances in Hematology & Oncology Pub Date : 2026-07-01

Matthew S Lee, Chloe T Shi, Tae-Hee Kim, Gianni A Morales Martinez, Ranveer Vasdev, Mark Waddle, Naoki Takahashi, Stephen A Boorjian, Abhinav Khanna

{"title":"Artificial intelligence in prostate cancer diagnosis and management: state-of-the-art approaches and emerging innovations.","authors":"Matthew S Lee, Chloe T Shi, Tae-Hee Kim, Gianni A Morales Martinez, Ranveer Vasdev, Mark Waddle, Naoki Takahashi, Stephen A Boorjian, Abhinav Khanna","doi":"","DOIUrl":"","url":null,"abstract":"Artificial intelligence (AI) is rapidly changing the field of medicine, and prostate cancer is no exception. The significant heterogeneity that characterizes the natural history of prostate cancer often leads to under- or overtreatment. Moreover, the already substantial burden of prostate cancer care on the health care system is predicted to rise significantly. By discerning patterns within immense, complex datasets, AI has the potential to augment the diagnosis, risk stratification, and treatment of prostate cancer beyond what is possible with existing clinical tools. In recent years, AI algorithms have achieved impressive diagnostic accuracy in the realms of imaging and histopathology interpretation, and AI-based biomarkers for risk stratification have been incorporated into major clinical guidelines. Early strides have also been made in radiation treatment planning, intraoperative surgical assistance and surgical education, and quality control. Moving forward, the prospective validation of novel AI algorithms across large, multi-institutional datasets is needed to minimize bias and ensure validity. Furthermore, it is the responsibility of providers across the continuum of prostate cancer care to ensure the safe and ethical integration of AI into clinical practice. This review summarizes the current state of AI applications in the diagnosis, risk stratification, and treatment of prostate cancer, highlighting recent advances and emerging opportunities in this ever-changing field.","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"24 5","pages":"292-300"},"PeriodicalIF":2.0,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148702808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of toxicities due to immune checkpoint inhibitors. 免疫检查点抑制剂引起的毒性的管理。

IF 2

Clinical Advances in Hematology & Oncology Pub Date : 2026-07-01

Pankti Reid

引用次数: 0

Molecular residual disease (MRD) testing: advancing clinical decision-making in breast cancer. 分子残留病（MRD）检测：促进乳腺癌临床决策

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2026-06-01

Jason A Mouabbi, Marla D Lipsyc-Sharf, Fengting Yan

{"title":"Molecular residual disease (MRD) testing: advancing clinical decision-making in breast cancer.","authors":"Jason A Mouabbi, Marla D Lipsyc-Sharf, Fengting Yan","doi":"","DOIUrl":"","url":null,"abstract":"Circulating tumor DNA (ctDNA) is emerging as a clinically meaningful biomarker across multiple solid tumors, including breast cancer. Advances in personalized, tumor-informed whole-genome sequencing have enabled highly sensitive detection of ctDNA, allowing for more precise assessment of tumor burden. Across treatment settings, ctDNA testing has demonstrated consistent prognostic value in patients with breast cancer. In the neoadjuvant setting, ctDNA status is strongly prognostic at baseline and following completion of therapy. After definitive surgery, detection of molecular residual disease (MRD) by ctDNA testing is associated with a marked increased risk of recurrence, with positive predictive values approaching 100% and a lead time of approximately 13.5 months over conventional approaches. These data support the potential role of ctDNA testing as an adjunct to current surveillance strategies, with the aim of identifying recurrence before the onset of significant clinical symptoms. Although ctDNA results are not yet used to guide treatment modification outside of established standards of care, the field is advancing rapidly. Multiple ongoing prospective, interventional trials are evaluating MRDguided therapeutic strategies, and emerging evidence suggests that ctDNA may ultimately help individualize adjuvant therapy-either by identifying patients who may safely de-escalate treatment or by signaling when escalation could be beneficial. In the metastatic setting, ctDNA testing can complement radiographic assessment by providing an additional measure of treatment response, particularly in patients with nonmeasurable or difficult-to-visualize disease. Across all settings, ctDNA testing is most informative when performed longitudinally, enabling assessment of dynamic changes over time. Although baseline ctDNA testing provides valuable prognostic information, its absence at this time point or at diagnosis does not limit the utility of ctDNA assessment at subsequent time points.","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"24 4 Suppl 4","pages":"1-16"},"PeriodicalIF":1.1,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148229161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interpreting MRD results and integrating assays into practice. 解释MRD结果并将分析整合到实践中。

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2026-06-01

Marla D Lipsyc-Sharf

引用次数: 0

Clinical response with cabozantinib plus nivolumab, a first-line therapy in advanced renal cell carcinoma: a clinical case report. 卡博赞替尼联合纳武单抗一线治疗晚期肾细胞癌的临床疗效：临床病例报告

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2026-06-01

Pedro C Barata, Ivan Macharashvili

引用次数: 0